Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial

Cell Metabolism

Volumn 24, Issue 1, 2016, Pages 63-74

  Reijnders, Dorien ^a,b   Goossens, Gijs H ^a,b   Hermes, Gerben D A ^b,c   Neis, Evelien P J G ^a,b   van der Beek, Christina M ^a,b   Most, Jasper ^a   Holst, Jens J ^d   Lenaerts, Kaatje ^a,b   Kootte, Ruud S ^b,e   Nieuwdorp, Max ^b,e   Groen, Albert K ^b,f   Olde Damink, Steven W M ^a,g   Boekschoten, Mark V ^b,c   Smidt, Hauke ^b,c   Zoetendal, Erwin G ^b,c   Dejong, Cornelis H C ^a,b   Blaak, Ellen E ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY OF GRONINGEN   (Netherlands)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; INSULIN; PLACEBO; SHORT CHAIN FATTY ACID; VANCOMYCIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; BUTYRIC ACID;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BILE ACID METABOLISM; CONTROLLED STUDY; DISORDERS OF CARBOHYDRATE METABOLISM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENERGY EXPENDITURE; FATTY ACID BLOOD LEVEL; FIRMICUTES; FOLLOW UP; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLITE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANTIBODY SPECIFICITY; BLOOD; CELL SHAPE; CHEMISTRY; DRUG EFFECTS; ENERGY METABOLISM; ENZYME SPECIFICITY; FECES; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PERMEABILITY;

ADIPOCYTES; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BIOMARKERS; BUTYRIC ACID; CELL SHAPE; DOUBLE-BLIND METHOD; ENERGY METABOLISM; FECES; GASTROINTESTINAL MICROBIOME; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INSULIN; MALE; MIDDLE AGED; OBESITY; ORGAN SPECIFICITY; PERMEABILITY; PLACEBOS; SUBSTRATE SPECIFICITY; VANCOMYCIN;

EID: 84992381833     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.06.016     Document Type: Article

References (62)

1. Bäckhed, F., Ding, H., Wang, T., Hooper, L.V., Koh, G.Y., Nagy, A., Semenkovich, C.F., Gordon, J.I., The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 101 (2004), 15718–15723.
2. Bates, D., Mächler, M., Bolker, B., Walker, S., Fitting Linear Mixed-Effects Models Using lme4. J. Stat. Softw. 67 (2015), 1–48.
3. Bech-Nielsen, G.V., Hansen, C.H., Hufeldt, M.R., Nielsen, D.S., Aasted, B., Vogensen, F.K., Midtvedt, T., Hansen, A.K., Manipulation of the gut microbiota in C57BL/6 mice changes glucose tolerance without affecting weight development and gut mucosal immunity. Res. Vet. Sci. 92 (2012), 501–508.
4. Brehm, A., Krssak, M., Schmid, A.I., Nowotny, P., Waldhäusl, W., Roden, M., Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes 55 (2006), 136–140.
5. Brestoff, J.R., Artis, D., Commensal bacteria at the interface of host metabolism and the immune system. Nat. Immunol. 14 (2013), 676–684.
6. Brighton, C.A., Rievaj, J., Kuhre, R.E., Glass, L.L., Schoonjans, K., Holst, J.J., Gribble, F.M., Reimann, F., Bile acids trigger GLP-1 release predominantly by accessing basolaterally-located G-protein coupled bile acid receptors. Endocrinology 156 (2015), 3961–3970.
7. Canfora, E.E., Jocken, J.W., Blaak, E.E., Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11 (2015), 577–591.
8. Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A.M., Fava, F., Tuohy, K.M., Chabo, C., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56 (2007), 1761–1772.
9. Cani, P.D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A.M., Delzenne, N.M., Burcelin, R., Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57 (2008), 1470–1481.
10. Carvalho, B.M., Guadagnini, D., Tsukumo, D.M., Schenka, A.A., Latuf-Filho, P., Vassallo, J., Dias, J.C., Kubota, L.T., Carvalheira, J.B., Saad, M.J., Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice. Diabetologia 55 (2012), 2823–2834.
11. Chou, C.J., Membrez, M., Blancher, F., Gut decontamination with norfloxacin and ampicillin enhances insulin sensitivity in mice. Nestle Nutr. Workshop Ser. Pediatr. Program. 62 (2008), 127–137 discussion 137–140.
12. Cox, L.M., Blaser, M.J., Pathways in microbe-induced obesity. Cell Metab. 17 (2013), 883–894.
13. Cox, L.M., Blaser, M.J., Antibiotics in early life and obesity. Nat. Rev. Endocrinol. 11 (2015), 182–190.
14. DeFronzo, R.A., Tobin, J.D., Andres, R., Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 237 (1979), E214–E223.
15. Frayn, K.N., Calculation of substrate oxidation rates in vivo from gaseous exchange. J. Appl. Physiol. 55 (1983), 628–634.
16. Fukuda, S., Toh, H., Hase, K., Oshima, K., Nakanishi, Y., Yoshimura, K., Tobe, T., Clarke, J.M., Topping, D.L., Suzuki, T., et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469 (2011), 543–547.
17. Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504 (2013), 446–450.
18. Ganal, S.C., Sanos, S.L., Kallfass, C., Oberle, K., Johner, C., Kirschning, C., Lienenklaus, S., Weiss, S., Staeheli, P., Aichele, P., Diefenbach, A., Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 37 (2012), 171–186.
19. Gao, Z., Yin, J., Zhang, J., Ward, R.E., Martin, R.J., Lefevre, M., Cefalu, W.T., Ye, J., Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58 (2009), 1509–1517.
20. García-Villalba, R., Giménez-Bastida, J.A., García-Conesa, M.T., Tomás-Barberán, F.A., Carlos Espín, J., Larrosa, M., Alternative method for gas chromatography-mass spectrometry analysis of short-chain fatty acids in faecal samples. J. Sep. Sci. 35 (2012), 1906–1913.
21. Gonzales, M., Pepin, J., Frost, E.H., Carrier, J.C., Sirard, S., Fortier, L.C., Valiquette, L., Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect. Dis., 10, 2010, 363.
22. Goossens, G.H., Bizzarri, A., Venteclef, N., Essers, Y., Cleutjens, J.P., Konings, E., Jocken, J.W., Cajlakovic, M., Ribitsch, V., Clément, K., Blaak, E.E., Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation 124 (2011), 67–76.
23. Greenhill, C., Obesity: Gut microbiota, host genetics and diet interact to affect the risk of developing obesity and the metabolic syndrome. Nat. Rev. Endocrinol., 11, 2015, 630.
24. Hartstra, A.V., Bouter, K.E., Bäckhed, F., Nieuwdorp, M., Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care 38 (2015), 159–165.
25. Hulzebos, C.V., Renfurm, L., Bandsma, R.H., Verkade, H.J., Boer, T., Boverhof, R., Tanaka, H., Mierau, I., Sauer, P.J., Kuipers, F., Stellaard, F., Measurement of parameters of cholic acid kinetics in plasma using a microscale stable isotope dilution technique: application to rodents and humans. J. Lipid Res. 42 (2001), 1923–1929.
26. Hwang, I., Park, Y.J., Kim, Y.R., Kim, Y.N., Ka, S., Lee, H.Y., Seong, J.K., Seok, Y.J., Kim, J.B., Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity. FASEB J. 29 (2015), 2397–2411.
27. Jans, A., Konings, E., Goossens, G.H., Bouwman, F.G., Moors, C.C., Boekschoten, M.V., Afman, L.A., Müller, M., Mariman, E.C., Blaak, E.E., PUFAs acutely affect triacylglycerol-derived skeletal muscle fatty acid uptake and increase postprandial insulin sensitivity. Am. J. Clin. Nutr. 95 (2012), 825–836.
28. Jess, T., Microbiota, antibiotics, and obesity. N. Engl. J. Med. 371 (2014), 2526–2528.
29. Jones, M.L., Martoni, C.J., Ganopolsky, J.G., Labbé, A., Prakash, S., The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention. Expert Opin. Biol. Ther. 14 (2014), 467–482.
30. Kerr, C.A., Grice, D.M., Tran, C.D., Bauer, D.C., Li, D., Hendry, P., Hannan, G.N., Early life events influence whole-of-life metabolic health via gut microflora and gut permeability. Crit. Rev. Microbiol. 41 (2015), 326–340.
31. Kersten, S., Lichtenstein, L., Steenbergen, E., Mudde, K., Hendriks, H.F., Hesselink, M.K., Schrauwen, P., Müller, M., Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler. Thromb. Vasc. Biol. 29 (2009), 969–974.
32. Khan, M.T., Nieuwdorp, M., Bäckhed, F., Microbial modulation of insulin sensitivity. Cell Metab. 20 (2014), 753–760.
33. Kotronen, A., Seppälä-Lindroos, A., Bergholm, R., Yki-Järvinen, H., Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia 51 (2008), 130–138.
34. Liaw, A., Wiener, M., Classification and Regression by randomForest. R News 2 (2002), 18–22.
35. Lin, K., Kools, H., de Groot, P.J., Gavai, A.K., Basnet, R.K., Cheng, F., Wu, J., Wang, X., Lommen, A., Hooiveld, G.J., et al. MADMAX - Management and analysis database for multiple ∼omics experiments. J. Integr. Bioinform., 8, 2011, 160.
36. Marchesi, J.R., Adams, D.H., Fava, F., Hermes, G.D., Hirschfield, G.M., Hold, G., Quraishi, M.N., Kinross, J., Smidt, H., Tuohy, K.M., et al. The gut microbiota and host health: a new clinical frontier. Gut 65 (2015), 330–339.
37. McCutcheon, A.L., Latent class analysis. 1987, Sage.
38. Membrez, M., Blancher, F., Jaquet, M., Bibiloni, R., Cani, P.D., Burcelin, R.G., Corthesy, I., Macé, K., Chou, C.J., Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J. 22 (2008), 2416–2426.
39. Mikkelsen, K.H., Frost, M., Bahl, M.I., Licht, T.R., Jensen, U.S., Rosenberg, J., Pedersen, O., Hansen, T., Rehfeld, J.F., Holst, J.J., et al. Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism. PLoS ONE, 10, 2015, e0142352.
40. Mikkelsen, K.H., Knop, F.K., Frost, M., Hallas, J., Pottegård, A., Use of Antibiotics and Risk of Type 2 Diabetes: A Population-Based Case-Control Study. J. Clin. Endocrinol. Metab. 100 (2015), 3633–3640.
41. Million, M., Thuny, F., Angelakis, E., Casalta, J.P., Giorgi, R., Habib, G., Raoult, D., Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment. Nutr. Diabetes, 3, 2013, e87.
42. Most, J., Timmers, S., Warnke, I., Jocken, J.W., van Boekschoten, M., de Groot, P., Bendik, I., Schrauwen, P., Goossens, G.H., Blaak, E.E., Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial. Am. J. Clin. Nutr., 2016 Published online May 18, 2016. ajcn122937.
43. Murphy, E.F., Cotter, P.D., Hogan, A., O'Sullivan, O., Joyce, A., Fouhy, F., Clarke, S.F., Marques, T.M., O'Toole, P.W., Stanton, C., et al. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut 62 (2013), 220–226.
44. Oksanen, J., Blanchet, F.G., Kindt, R., Legendre, P., Minchin, P.R., O'Hara, R.B., Simpson, G.L., Solymos, P., Stevens, M.H.H., and Wagner, H. (2011). Package “vegan” version 2.0-2. http://cran.r-project.org/web/packages/vegan/index.html.
45. Proust-Lima, C., Philipps, V., and Liquet, B. (2015). Estimation of Extended Mixed Models Using Latent Classes and Latent Processes: the R package lcmm. https://arxiv.org/pdf/1503.00890.pdf.
46. Rajilić-Stojanović, M., Heilig, H.G., Molenaar, D., Kajander, K., Surakka, A., Smidt, H., de Vos, W.M., Development and application of the human intestinal tract chip, a phylogenetic microarray: analysis of universally conserved phylotypes in the abundant microbiota of young and elderly adults. Environ. Microbiol. 11 (2009), 1736–1751.
47. Rajpal, D.K., Klein, J.L., Mayhew, D., Boucheron, J., Spivak, A.T., Kumar, V., Ingraham, K., Paulik, M., Chen, L., Van Horn, S., et al. Selective Spectrum Antibiotic Modulation of the Gut Microbiome in Obesity and Diabetes Rodent Models. PLoS ONE, 10, 2015, e0145499.
48. Ridlon, J.M., Kang, D.J., Hylemon, P.B., Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47 (2006), 241–259.
49. Rune, I., Hansen, C.H., Ellekilde, M., Nielsen, D.S., Skovgaard, K., Rolin, B.C., Lykkesfeldt, J., Josefsen, K., Tranberg, B., Kihl, P., Hansen, A.K., Ampicillin-improved glucose tolerance in diet-induced obese C57BL/6NTac mice is age dependent. J. Diabetes Res., 2013, 2013, 319321.
50. Schoffelen, P.F., Westerterp, K.R., Saris, W.H., Ten Hoor, F., A dual-respiration chamber system with automated calibration. J. Appl. Physiol. (1985) 83 (1997), 2064–2072.
51. Schols, A.M., Buurman, W.A., Staal van den Brekel, A.J., Dentener, M.A., Wouters, E.F., Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51 (1996), 819–824.
52. Smyth, G.K., Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol., 3, 2004, Article3.
53. Steele, R., Influences of glucose loading and of injected insulin on hepatic glucose output. Ann. N Y Acad. Sci. 82 (1959), 420–430.
54. Thuny, F., Richet, H., Casalta, J.P., Angelakis, E., Habib, G., Raoult, D., Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. PLoS ONE, 5, 2010, e9074.
55. Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R., Gordon, J.I., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444 (2006), 1027–1031.
56. van Eijk, H.M., Bloemen, J.G., Dejong, C.H., Application of liquid chromatography-mass spectrometry to measure short chain fatty acids in blood. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877 (2009), 719–724.
57. van Wijck, K., Verlinden, T.J., van Eijk, H.M., Dekker, J., Buurman, W.A., Dejong, C.H., Lenaerts, K., Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: a randomized controlled crossover trial. Clin. Nutr. 32 (2013), 245–251.
58. Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A.G., Holst, J.J., Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 88 (2003), 2706–2713.
59. Vrieze, A., de Groot, P.F., Kootte, R.S., Knaapen, M., van Nood, E., Nieuwdorp, M., Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease?. Best Pract. Res. Clin. Gastroenterol. 27 (2013), 127–137.
60. Vrieze, A., Out, C., Fuentes, S., Jonker, L., Reuling, I., Kootte, R.S., van Nood, E., Holleman, F., Knaapen, M., Romijn, J.A., et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J. Hepatol. 60 (2014), 824–831.
61. Weir, J.B., New methods for calculating metabolic rate with special reference to protein metabolism. J. Physiol. 109 (1949), 1–9.
62. Yap, I.K., Li, J.V., Saric, J., Martin, F.P., Davies, H., Wang, Y., Wilson, I.D., Nicholson, J.K., Utzinger, J., Marchesi, J.R., Holmes, E., Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J. Proteome Res. 7 (2008), 3718–3728.